Eric Kmiec

Founder & Chief Executive Officer CorriXR Therapeutics

Dr. Kmiec is a pioneering molecular biologist and a leading authority in gene editing and genetic therapies. He is the Founder and Executive Director of ChristianaCare’s Gene Editing Institute, where he has spearheaded groundbreaking research in CRISPR-based technologies, particularly targeting inherited disorders and cancer. Dr. Kmiec is also the Founder and CEO of CorriXR Therapeutics advacing in vivo CRISPR directed gene editing for the treatment of squamous cell carcinoma. He holds academic appointments at the University of Delaware and the Wistar Institute. His work has been featured mutiple times in Scientific American, STAT News, PBS, CRISPR Medicine News, The Philadelphia Inquirer, and The New York Times, highlighting the impact on innovative therapies and public discourse.

Seminars

Thursday 30th July 2026
In Vivo Gene Editing for the Treatment of Squamous Cell Carcinomas, a Direct Platform Approach
9:30 am
  • CRISPR directed gene editing of master regulator genes controlling oncogenesis in cutaneous squamous cell carcinoma
  • Tumor cell specific disruption of NRF2 and EGFR genes as a platform approach to the treatment of squamous cell carcinoma of the lung
  • Direct delivery strategies for enhancing the effectiveness of gene editing in cancer treatment
Eric Kmiec of CorriXR Therapeutics - 5th In Vivo Cell Engineering & Gene Editing Summit
View all Speakers
View Event Brochure